Naranol hydrochloride

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341556

CAS#: 34256-91-2

Description: Naranol hydrochloride is a biochemical.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-09-20. Prices are subject to change without notice.

Naranol hydrochloride is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 341556
Name: Naranol hydrochloride
CAS#: 34256-91-2
Chemical Formula: C18H22ClNO2
Exact Mass: 319.1339
Molecular Weight: 319.829
Elemental Analysis: C, 67.60; H, 6.93; Cl, 11.08; N, 4.38; O, 10.00

Synonym: Naranol hydrochloride; W 5494A; W-5494A; W5494A; W 5494 A.

IUPAC/Chemical Name: 7aH-Naphtho(1',2':5,6)pyrano(3,2-c)pyridin-7a-ol, 8,9,10,11,11a,12-hexahydro-8,10-dimethyl-, hydrochloride


InChi Code: InChI=1S/C18H21NO2.ClH/c1-12-10-19(2)11-14-9-16-15-6-4-3-5-13(15)7-8-17(16)21-18(12,14)20;/h3-8,12,14,20H,9-11H2,1-2H3;1H


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Lin HW, Simonavice CA, Lu CR, Lin WL, Wu PL, Chou CY, Liao CH, Lane HY. Severe hypertriglyceridemia secondary to venlafaxine use in an older adult on dialysis -case report. BMC Health Serv Res. 2017 Apr 13;17(1):272. doi: 10.1186/s12913-017-2195-2. PubMed PMID: 28407764; PubMed Central PMCID: PMC5390401.

2: Kaufman MB, Pham T, Parameswaran L, Choy M. Prasugrel hypersensitivity with respiratory distress and rash. Am J Health Syst Pharm. 2016 Jul 15;73(14):1051-7. doi: 10.2146/ajhp150327. PubMed PMID: 27385702.

3: McKean J, Watts H, Mokszycki R. Breakthrough seizures after starting vilazodone for depression. Pharmacotherapy. 2015 Mar;35(3):e6-8. doi: 10.1002/phar.1549. PubMed PMID: 25809181.

4: Štuhec M. Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature. Wien Klin Wochenschr. 2015 Sep;127(17-18):703-6. doi: 10.1007/s00508-014-0688-0. Epub 2015 Jan 10. Review. PubMed PMID: 25576334.

5: Ferreira PG, Costa S, Dias N, Ferreira AJ, Franco F. Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine. J Bras Pneumol. 2014 May-Jun;40(3):313-8. English, Portuguese. PubMed PMID: 25029655; PubMed Central PMCID: PMC4109204.

6: Williams MF, Maloof JA 3rd. Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel. Am J Health Syst Pharm. 2014 Jul 1;71(13):1097-100. doi: 10.2146/ajhp130518. PubMed PMID: 24939499.

7: Iuppa CA, Diefenderfer LA. Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine. Ann Pharmacother. 2013 Sep;47(9):1223-8. doi: 10.1177/1060028013503132. PubMed PMID: 24259741.

8: Angelo LJ, Lee KC. Dose-related paresthesias with venlafaxine. J Pharm Pract. 2013 Oct;26(5):514-7. doi: 10.1177/0897190013489573. Epub 2013 Jun 13. PubMed PMID: 23764565.

9: Kaufman KR, Podolsky D, Greenman D, Madraswala R. Antidepressant-selective gynecomastia. Ann Pharmacother. 2013 Jan;47(1):e6. doi: 10.1345/aph.1R491. Epub 2013 Jan 16. PubMed PMID: 23324513.

10: Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, Sportiello L, Parretta E, Rinaldi B, Panei P, Rossi F, Capuano A. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. J Child Adolesc Psychopharmacol. 2012 Dec;22(6):415-22. doi: 10.1089/cap.2012.0003. PubMed PMID: 23234585.

11: Nazer LH, Shankar G, Ali BA, Al-Najjar T. Fatal agranulocytosis associated with psychotropic medication use. Am J Health Syst Pharm. 2012 May 15;69(10):863-7. doi: 10.2146/ajhp110195. PubMed PMID: 22555081.

12: Kruithof MK, Bruins NA, van Roon EN. Coma after overdose with duloxetine. Ann Pharmacother. 2011 Jan;45(1):e5. doi: 10.1345/aph.1P432. Epub 2010 Dec 21. PubMed PMID: 21177420.

13: Steidl KE, Darko W, Probst LA, Noviasky JA, Nasser S. Rhabdomyolysis associated with phentermine. Am J Health Syst Pharm. 2010 Nov 15;67(22):1929-32. doi: 10.2146/ajhp090395. PubMed PMID: 21048209.

14: Prlesi L, Plakogiannis R. Angioedema after nonsteroidal antiinflammatory drug initiation in a patient stable on an angiotensin-converting-enzyme inhibitor. Am J Health Syst Pharm. 2010 Aug 15;67(16):1351-3. doi: 10.2146/ajhp090348. PubMed PMID: 20689124.

15: Charniot JC, Vignat N, Monsuez JJ, Kidouche R, Avramova B, Artigou JY, Albertini JP. Cardiogenic shock associated with reversible dilated cardiomyopathy during therapy with regular doses of venlafaxine. Am J Emerg Med. 2010 Feb;28(2):256.e1-5. doi: 10.1016/j.ajem.2009.05.010. PubMed PMID: 20159409.

16: Kelesidis T, Kelesidis I. Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin. Clin Ther. 2009 Dec;31(12):2894-9. doi: 10.1016/j.clinthera.2009.12.008. PubMed PMID: 20110028.

17: Glance LE, Cumpston A, Kanate A, Remick SC. Bendamustine-associated hemolytic anemia. Ann Pharmacother. 2009 Nov;43(11):1903-6. doi: 10.1345/aph.1M329. Epub 2009 Oct 6. PubMed PMID: 19809007.

18: Giannikopoulos G, Zorzou MP, Stamoulis I, Panagi G, Sitaras P, Georgopoulos I, Hadjileontis C, Malakos I, Kyriazis J. Cinacalcet-induced leukocytoclastic vasculitis. Am J Kidney Dis. 2009 Aug;54(2):e5-8. doi: 10.1053/j.ajkd.2009.02.019. Epub 2009 Jun 28. PubMed PMID: 19560849.

19: Stevens DL. Duloxetine-associated tachycardia. Ann Pharmacother. 2008 Oct;42(10):1511-3. doi: 10.1345/aph.1L108. Epub 2008 Aug 26. PubMed PMID: 18728105.

20: Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother. 2008 Jun;42(6):882-7. doi: 10.1345/aph.1L031. Epub 2008 Apr 29. PubMed PMID: 18445706.